AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Mmbg Investment Advisors CO.

Mmbg Investment Advisors CO. boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 28.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 7,459 shares of the company’s stock after acquiring an additional 1,650 shares during the period. Mmbg Investment Advisors CO.’s holdings in AstraZeneca were worth $489,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Banque Transatlantique SA bought a new stake in AstraZeneca during the fourth quarter worth approximately $26,000. Albion Financial Group UT increased its holdings in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after acquiring an additional 248 shares during the last quarter. CoreCap Advisors LLC grew its holdings in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after purchasing an additional 155 shares in the last quarter. Golden State Wealth Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth $55,000. Finally, Crews Bank & Trust bought a new position in shares of AstraZeneca during the fourth quarter worth about $55,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on AZN. BNP Paribas assumed coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price on the stock. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Finally, Morgan Stanley started coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca currently has an average rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $67.57 on Monday. The firm has a fifty day moving average price of $71.33 and a 200-day moving average price of $69.65. The stock has a market cap of $209.55 billion, a PE ratio of 29.90, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.06 earnings per share. Equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.